ArticleCureus2026
Unmasking Hemophagocytic Lymphohistiocytosis After Minimal Tumor Necrosis Factor-Alpha (TNF-α) Blockade: An Interplay of Contributing Elements.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Presented is a case of hemophagocytic lymphohistiocytosis (HLH) in a 25-year-old African American female patient with Behçet disease and seronegative rheumatoid arthritis who developed fever, nausea, vomiting, and diarrhea 14 days after her first adalimumab dose. The diagnosis was established based on clinical and laboratory parameters meeting five of eight HLH-2004 criteria. The temporal relationship between drug initiation and symptom onset, along with prior improvement in arthritis symptoms, favored drug-induced HLH over macrophage activation syndrome. The patient was successfully treated with high-dose dexamethasone monotherapy per the HLH-2004 protocol, with etoposide deferred given the suspected drug-induced etiology and normal NK activity, achieving clinical improvement within 48 to 72 hours. This case demonstrates that HLH can occur after minimal tumor necrosis factor-alpha inhibitor exposure, likely through idiosyncratic mechanisms potentiated by multiple autoimmune conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.